The Office of Clinical Trials (OCT) is the epicenter for human subjects research at the University of Wisconsin-Madison. Established in 1988, OCT is a centralized, disease-agnostic resource, serving investigators, study teams, and sponsors by delivering enterprise-wide leadership, standards and common infrastructure. OCT provides à la carte and bundled services for both sponsor- and investigator-initiated clinical research. Our research professionals are skilled in assessing, activating, conducting and reporting of clinical research in both pediatric and adult populations.
In collaboration with the Institute for Clinical and Translational Research, the UW Carbone Cancer Center (UWCCC) Clinical Research Central Office and others, we are advancing medical discoveries and providing innovations for the prevention, detection and treatment of disease to UW Health patients and Wisconsin communities.
108 INVESTIGATORS SUPPORTED
224 ACTIVE STUDIES
Services
Financial Management
Fiscal administration beginning with budget development, negotiation and contract routing, through sponsor invoicing, collection and fiscal reconciliation, ending with study closure
ClinicalTrials.gov Reporting
A centralized service to assist investigators with registration, maintenance and results reporting of applicable clinical trials as required by NIH & FDA
IRB Submissions
Preparation of Institutional Review Board (IRB) submissions including initial applications, protocol amendments, emergency use, continuing reviews, study completion, safety reports and more
Oncore
OCT facilitates and confirms all requirements of the ancillary review and study sign off process for both the UWCCC and ICTR instances of Oncore
Research Coordination
Professional research staff adept at conducting feasibility assessments, recruiting and consenting participants, collecting data and specimens, completing case report forms and more
Sponsor Engagement
An entry portal for industry sponsors seeking to partner with our skilled clinicians, experienced research staff and active patient population